(Direct) Healthcare Professional Communications

Important information on the revised information for healthcare professionals for Voluven 6% balanced, solution for infusion, and the revised training material as part of the controlled access programme (CAP)

13.08.2024

DHPC – Rabipur (virus rabiei inactivatus)

Berichte über Partikel nach der Rekonstitution - Empfehlungen zur Minimierung des Risikos für Partikel

19.07.2024

DHPC – Nuwiq (simoctocogum alfa)

Wichtige Information: Packungsbeilage entspricht nicht der aktuellen Version

Results 1 - 12 of 120

Swissmedic
Safety of Medicines
Hallerstrasse 7
3012 Berne
Switzerland

Newsletter

DHPC/HPC – Direct Healthcare Professional Communications

Schweizerisches Heilmittelinstitut
Institut suisse des produits thérapeutiques
Istituto svizzero per gli agenti terapeutici
Swiss Agency for Therapeutic Products

Swissmedic

(Direct) Healthcare Professional Communications

DHPC – Eylea® (afliberceptum)

DHPC – Rhophylac® (immunoglobulinum humanum anti-D)

DHPC – Comirnaty® JN.1 (bretovameranum)

DHPC – Vincristin-Teva® (vincristini sulfas)

DHPC – Spikevax JN.1 (mRNA-1273.167), Dispersion zur Injektion

DHPC – Glatirameracetat (Copaxone®, Glatiramyl®)

DHPC – Ceprotin 1000 IE, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung

DHPC – Mögliche Beinträchtigung der Sterilität der beiliegenden Nadelpakete

DHPC – Zemplar (paricalcitolum)

DHPC – Measures to minimise risks from solutions for infusion containing hydroxyethyl starch (HES)

DHPC – Rabipur (virus rabiei inactivatus)

DHPC – Nuwiq (simoctocogum alfa)

Newsletter

Overview:

Archive HPC

Guidance document DHPC

Main Navigation

Search

Breadcrumb

(Direct) Healthcare Professional Communications

Overview:

Supplementary information

Archive HPC

Guidance document DHPC